ArticleHaematologica2020

Modulated expression of adhesion, migration and activation molecules may predict the degree of response in chronic lymphocytic leukemia patients treated with ibrutinib plus rituximab.

Nadia Peragine et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.